Peptide research, regulation, discovery. Every story links to the peptide it’s about.
RSSA retrospective cohort in Plastic and Reconstructive Surgery analyzed 552 abdominal body contouring patients between 2013 and 2025. Combined bariatric + GLP-1 weight loss predicted seroma (OR 3.05), hematoma (OR 3.74), and unplanned return to the operating room (OR 6.78), independent of total weight lost.
A 16-week double-blind randomized trial in JAMA Psychiatry reports that semaglutide significantly improved effort-based decision-making in patients with major depressive disorder. Computational modeling showed the effect was driven by reduced effort discounting, with sensitivity to reward probability unchanged. First RCT evidence that GLP-1 drugs touch the reward circuitry in clinical depression.
A JMCP analysis of 2023 pharmacy claims found that state-level GLP-1 utilization for diabetes tracks diabetes prevalence in commercial plans, but state-level utilization for obesity barely correlates with obesity prevalence. The driver is Medicaid coverage policy, which varies dramatically state-to-state and creates a two-tier access map underneath the federal coverage debate.
A target-trial emulation in 333,687 Veterans Affairs patients found similar all-cause acute pancreatitis rates between GLP-1 and sulfonylurea users at one year. But drug-induced pancreatitis was up early in the GLP-1 arm, while hypertriglyceridemia and alcohol-related pancreatitis were down later. Net increased risk concentrates in the first two to three months.
OrbiMed-incubated Pinnacle Medicines closed an oversubscribed $89 million Series B for oral peptide therapeutics designed to match injectable-biologic efficacy in asthma, COPD, immunology, and inflammation. The round signals that the peptide capital flow is finally widening beyond GLP-1.
Boehringer and Zealand reported 16.6% mean weight loss at 76 weeks for survodutide in Phase 3 SYNCHRONIZE-1, versus 3.2% on placebo, with predominantly fat-mass loss and 85.1% of treated patients clearing the 5% threshold. The same announcement advanced BI 3034701, a triple GLP-1/GIP/NPY2 agonist, into Phase 2 mid-2026.
An American Journal of Sports Medicine review surveys BPC-157, TB-500, CJC-1295 + ipamorelin, tesamorelin, and GHK-Cu, the injectable peptides driving sports-medicine patient demand. The review's verdict is that preclinical evidence is real, human evidence is essentially absent, and the orthopedic community wants research infrastructure paired with any access decision the FDA makes in July.
A C&EN feature surveys three amylin obesity candidates (Novo cagrilintide, Lilly eloralintide, Roche/Zealand petrelintide). Phase 2 has not delivered the muscle-preservation or GI-tolerance profile early investors expected. CagriSema's Phase 3 head-to-head against tirzepatide is the readout that decides the case.
Four authors at Emory, Penn, and Ohio State, funded by Arnold Ventures, argue in Nature Medicine that digital twins and in silico clinical trials are arriving in drug development, and that only structured input from regulators and the public sector can make these tools reliable evidence for approval.
A mouse study in Neuropharmacology mapped GLP-1 receptors across the cerebellum using four methods and found them in granule cells, mossy fibers, and the deep cerebellar nuclei. The cerebellum projects to the brain's reward circuit, suggesting a new piece of why Wegovy-class drugs work.
Mutant p53 has resisted small-molecule drug development for decades. A new mouse study uses an intranasal peptide vaccine instead, and reports smaller tumors, longer survival, and stronger T-cell infiltration in vaccinated animals carrying a Trp53 R270H mutation.
RoBERTcr is a 152-million-parameter language model trained specifically on T-cell receptor sequences. A new Bioinformatics paper reports it beats Meta's ESM and other general protein language models on TCR-peptide binding prediction, and learns the binding interface from sequence alone.
An Endocrine Reviews paper argues that GLP-1 and orexin, two peptide systems usually treated separately, are dysregulated together in long COVID and chronic fatigue. The therapeutic implication: combine GLP-1 drugs with orexin-targeting medication.
A 173,216-patient cohort with type 2 diabetes and pre-existing diabetic retinopathy showed GLP-1 users had lower progression to proliferative retinopathy (HR 0.78), retinal vein occlusion (HR 0.70), and neovascular glaucoma (HR 0.65). NAION risk was null (HR 0.88, CI 0.54-1.44).
Boehringer Ingelheim's Phase 3 SYNCHRONIZE-1 trial cleared its 76-week primary endpoint visit, with topline expected H1 2026. Survodutide is a GLP-1/glucagon dual agonist co-developed with Zealand Pharma, positioning to enter the obesity drug market behind semaglutide and tirzepatide.